Day: October 14, 2025

LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA. Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Guggenheim representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio)...

VANCOUVER, B.C., Oct. 14, 2025 (GLOBE NEWSWIRE) — via IBN – Fairchild Gold Corp. (“Fairchild” or the “Company”) (TSXV: FAIR), is pleased to announce a non-brokered private placement financing (the “Offering”). The fully committed placement, the majority of which is being subscribed by a European Strategic Investor, is expected to close on or about October 17, 2025, subject to customary regulatory approvals. The Offering will consist of up to 12,222,222 units (the “Units”) at a price of C$0.09 per Unit, for total gross proceeds of approximately C$1,100,000. Each Unit will consist of one common share in the capital of the Company (each, a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one additional Share at a price of $0.15 per Share for a period of five years...

Legal action, including steps to file a John Doe lawsuit, to address suspected dissemination of false information, defamation, and libel against the Company and executives, as well as potential unlawful trading practices  CEO Kevin Kelly stated, “We are deeply concerned about the harm inflicted on our shareholders by coordinated efforts to spread misinformation and manipulate our stock price.” MCLEAN, Va., Oct. 14, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, announces today that over the past 5-6 months, the Company’s cybersecurity team has employed advanced cyber techniques, leveraging our proprietary technology, to monitor and identify individuals on platforms such as X (formerly Twitter), Stocktwits, Reddit, Yahoo, and others who appear to have...

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease Celularity PDA-002 achieved durable wound healing with just two intramuscular doses As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients.FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized,...

OMAHA, Neb., Oct. 14, 2025 (GLOBE NEWSWIRE) — CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22 to 23 at The Hard Rock Hotel in New York City. Maxim Growth SummitDates: October 22-23, 2025Location: Midtown, New YorkAttendees: Clayton Adams, Chief Executive Officer, and Marco Margiotta, Chief Investment OfficerPanel Date and Time: Thursday, October 23, 2025, at 10:00 am E.T. To schedule a one-on-one meeting with CleanCore’s management team, please email KCSA Strategic Communications at CleanCore@KCSA.com. Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap...

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright Liver Disease Conference being held October 21 – 22, 2025. A webcast of the presentation will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the...

DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025. The Company will also be conducting a Learning Lounge at IDWeek 2025 on Tuesday, October 21, 2025, 1:15 pm EST. The title of the presentation is ‘An Overview of Urinary Tract Infection in Adult Women: Focus on Oral Sulopenem.’ Presenters: Steven I. Aronin, M.D. and Michael Dunne, M.D. Data to be presented at IDWeek 2025 include: Presentation Title: Risk factors for treatment failure...

Technology platform again powers top-tier HEDIS results for Clover Health Medicare Advantage plans SAN FRANCISCO, Oct. 14, 2025 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered value-based care enablement company, today announced that its technology platform has once again powered top-tier HEDIS results for Clover Health Medicare Advantage plans through its AI-driven flywheel. The company is now making this unparalleled HEDIS platform available to third-party partners for the first time. As with last year, Counterpart has enabled Clover Health to be the #1 performing PPO plan in the country for HEDIS clinical quality measures for plans over 2,000 members. Clover is again...

The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the FDA-cleared LIBERTY® System. The Company is expected to initiate the limited market release of the LIBERTY® System during the current fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology conference, which is the largest Interventional Radiology conference in the U.S. The 3PL company...

CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, presented positive preclinical data in a poster at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research that took place from September 28 through October 1, 2025, in Boston, Massachusetts. The poster highlighted preclinical data from CLR 121225 (CLR 225), the Company’s novel actinium-based radio conjugate alpha-emitter for treatment...